

# Jeffrey Aronson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7726528/publications.pdf>

Version: 2024-02-01

342  
papers

19,476  
citations

24978

57  
h-index

12910

131  
g-index

368  
all docs

368  
docs citations

368  
times ranked

22878  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global, regional, and national consumption of controlled opioids: a cross-sectional study of 214 countries and non-metropolitan territories. <i>British Journal of Pain</i> , 2022, 16, 34-40.	0.7	22
2	Deaths from cardiovascular disease involving anticoagulants: a systematic synthesis of coronersâ€™ case reports. <i>BJGP Open</i> , 2022, 6, BJGPO.2021.0150.	0.9	11
3	Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity. <i>Drug Safety</i> , 2022, 45, 137-144.	1.4	15
4	When I use a word . . . . New medical words 1422â€™1972. <i>BMJ, The</i> , 2022, 376, o187.	3.0	2
5	When I use a word . . . . Lexicographical anniversaries. <i>BMJ, The</i> , 2022, 376, o105.	3.0	1
6	Sales of Over-the-Counter Products Containing Codeine in 31 Countries, 2013â€™2019: A Retrospective Observational Study. <i>Drug Safety</i> , 2022, 45, 237-247.	1.4	14
7	When I use a word . . . . Medical anniversaries in 2022. <i>BMJ, The</i> , 2022, 376, o39.	3.0	3
8	When I use a word . . . . Medical words newly logged in the OED in September 2021. <i>BMJ, The</i> , 2022, 376, o255.	3.0	2
9	When I use a word . . . . Vaccinationâ€™rights and duties. <i>BMJ, The</i> , 2022, 376, o317.	3.0	0
10	When I use a word . . . . St Bartholomewâ€™onomastics and reputation. <i>BMJ, The</i> , 2022, 376, o370.	3.0	1
11	When I use a word . . . . Medical patronymics, metronymics, and papponymics. <i>BMJ, The</i> , 2022, 376, o437.	3.0	1
12	When I use a word . . . . Medical trigger warnings. <i>BMJ, The</i> , 2022, 376, o579.	3.0	0
13	When I use a word . . . . Diagnosis. <i>BMJ, The</i> , 2022, 376, o747.	3.0	2
14	When I use a word . . . . Memory, semantic and episodic. <i>BMJ, The</i> , 2022, 376, o804.	3.0	3
15	When I use a word . . . . Listening to the patient. <i>BMJ, The</i> , 2022, 376, o646.	3.0	8
16	When I use a word . . . . Bioscience journalsâ€™an open and shut case?. <i>BMJ, The</i> , 2022, 376, o536.	3.0	0
17	When I use a word . . . . Medical aphorisms. <i>BMJ, The</i> , 2022, 377, o934.	3.0	0
18	Blood pressure meta-analysis highlights an implementation gap. <i>Lancet, The</i> , 2022, 399, 1379-1380.	6.3	1

#	ARTICLE	IF	CITATIONS
19	When I use a word . . . Remembrance of things past. BMJ, The, 2022, 377, o873.	3.0	1
20	Deaths attributed to the use of medications purchased online. BMJ Evidence-Based Medicine, 2022, 27, 60-64.	1.7	18
21	Preventable deaths from SARS-CoV-2 in England and Wales: a systematic case series of coroners' reports during the COVID-19 pandemic. BMJ Evidence-Based Medicine, 2022, 27, 296-304.	1.7	8
22	CARE guidelines for case reports: explanation and elaboration document. Translation into Russian. Digital Diagnostics, 2022, 3, 16-42.	0.3	4
23	When I use a word . . . Medical hyacinths. BMJ, The, 2022, 377, o1036.	3.0	0
24	When I use a word . . . Medical magic. BMJ, The, 2022, 377, o1092.	3.0	1
25	When I use a word . . . More medical magic. BMJ, The, 2022, 377, o1154.	3.0	0
26	Artificial Intelligence in Pharmacovigilance: An Introduction to Terms, Concepts, Applications, and Limitations. Drug Safety, 2022, 45, 407-418.	1.4	17
27	When I use a word . . . Some words about the climate. BMJ, The, 2022, 377, o1222.	3.0	0
28	The problem of look-alike, sound-alike name errors: Drivers and solutions. British Journal of Clinical Pharmacology, 2021, 87, 386-394.	1.1	30
29	Forgotten Primodos story and the roles of general practitioners. BMJ Evidence-Based Medicine, 2021, 26, 79-81.	1.7	1
30	The use of mechanistic reasoning in assessing coronavirus interventions. Journal of Evaluation in Clinical Practice, 2021, 27, 684-693.	0.9	8
31	A systematic literature review of LASA error interventions. British Journal of Clinical Pharmacology, 2021, 87, 336-351.	1.1	6
32	Coroners' concerns to prevent harms: a series of coroners' case reports to serve patient safety and educate the public, clinicians and policy-makers. BMJ Evidence-Based Medicine, 2021, 26, 37-38.	1.7	13
33	Analysis of reports of unintended pregnancies associated with the combined use of non-enzyme-inducing antibiotics and hormonal contraceptives. BMJ Evidence-Based Medicine, 2021, 26, 112-113.	1.7	10
34	Extracting data from diagnostic test accuracy studies for meta-analysis. BMJ Evidence-Based Medicine, 2021, 26, 19-21.	1.7	2
35	Dealing with categorical risk data when extracting data for meta-analysis. BMJ Evidence-Based Medicine, 2021, 26, 43-45.	1.7	3
36	Combining and converting groups when extracting data for meta-analysis. BMJ Evidence-Based Medicine, 2021, 26, 85-87.	1.7	4

#	ARTICLE	IF	CITATIONS
37	Summarising good practice guidelines for data extraction for systematic reviews and meta-analysis. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 88-90.	1.7	33
38	The Oxford Catalogue of Opioids: A systematic synthesis of opioid drug names and their pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3790-3812.	1.1	8
39	Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. <i>BMJ</i> , The, 2021, 374, n1537.	3.0	88
40	Long-term monitoring in primary care for chronic kidney disease and chronic heart failure: a multi-method research programme. <i>Programme Grants for Applied Research</i> , 2021, 9, 1-218.	0.4	1
41	When I use a word . . . . The efficiency paradox. <i>BMJ</i> , The, 2021, 375, n2712.	3.0	1
42	When I use a word . . . . No jab, no job? A benefit:harm balance analysis. <i>BMJ</i> , The, 2021, 375, n2934.	3.0	3
43	When I use a word . . . . Examining the efficiency paradox. <i>BMJ</i> , The, 2021, 375, n2856.	3.0	0
44	When I use a word . . . . Taking therapeutic care. <i>BMJ</i> , The, 2021, 375, n3010.	3.0	2
45	When I use a word . . . . The Precautionary Principle: a definition. <i>BMJ</i> , The, 2021, 375, n3111.	3.0	3
46	When I use a word . . . . The Precautionary Principle: a brief history. <i>BMJ</i> , The, 2021, 375, n3059.	3.0	5
47	Medical Devices: Classification and Analysis of Faults Leading to Harms. <i>Drug Safety</i> , 2020, 43, 95-102.	1.4	2
48	Naltrexone&#x2013;bupropion (Mysimba) in management of obesity: A systematic review and meta&#x2013;analysis of unpublished clinical study reports. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 646-667.	1.1	28
49	Medical Devices: Definition, Classification, and Regulatory Implications. <i>Drug Safety</i> , 2020, 43, 83-93.	1.4	47
50	Extending anticoagulation treatment for unprovoked venous thromboembolism. <i>BMJ Evidence-Based Medicine</i> , 2020, 25, 184-186.	1.7	1
51	Me&#x2013;too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2114-2122.	1.1	37
52	Drugs and the renin-angiotensin system in covid-19. <i>BMJ</i> , The, 2020, 369, m1313.	3.0	89
53	Defining Aspects of Mechanisms: Evidence-Based Mechanism (Evidence for a Mechanism), Mechanism-Based Evidence (Evidence from a Mechanism), and Mechanistic Reasoning. <i>Boston Studies in the Philosophy and History of Science</i> , 2020, , 3-38.	0.4	9
54	Single screening or double screening for study selection in systematic reviews?. <i>BMJ Evidence-Based Medicine</i> , 2020, 25, 149-150.	1.7	11

#	ARTICLE	IF	CITATIONS
55	Relation between opioid consumption and inclusion of opioids in 137 national essential medicines lists. <i>BMJ Global Health</i> , 2020, 5, e003563.	2.0	18
56	Trends in kidney function testing in UK primary care since the introduction of the quality and outcomes framework: a retrospective cohort study using CPRD. <i>BMJ Open</i> , 2019, 9, e028062.	0.8	11
57	Key concepts for making informed choices. <i>Nature</i> , 2019, 572, 303-306.	13.7	28
58	Crisis in the supply of medicines. <i>BMJ: British Medical Journal</i> , 2019, 367, l5841.	2.4	11
59	Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e030596.	0.8	12
60	Introducing the EBM Verdict: research evidence relevant to clinical practice. <i>BMJ Evidence-Based Medicine</i> , 2019, 24, 85-86.	1.7	2
61	The British Pharmacological Society's WDM Paton Memorial Lecture 2019: How doctors were informed about pharmaceutical products through advertising in the <i>British Medical Journal</i> from 1955/6 to 1985/6. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1901-1906.	1.1	3
62	Single or dual antiplatelet therapy after a transient ischaemic attack or minor ischaemic stroke?. <i>BMJ Evidence-Based Medicine</i> , 2019, 24, 196-197.	1.7	0
63	Susceptibility to adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2205-2212.	1.1	24
64	Adverse events in people taking macrolide antibiotics versus placebo for any indication. <i>The Cochrane Library</i> , 2019, 2019, CD011825.	1.5	55
65	STROCCS 2019 Guideline: Strengthening the reporting of cohort studies in surgery. <i>International Journal of Surgery</i> , 2019, 72, 156-165.	1.1	1,248
66	Withdrawn medicines included in the essential medicines lists of 136 countries. <i>PLoS ONE</i> , 2019, 14, e0225429.	1.1	7
67	Sodium valproate: who knew what and when? Cumulative meta-analysis gives extra insights. <i>BMJ Evidence-Based Medicine</i> , 2019, 24, 127-129.	1.7	3
68	Comparison of essential medicines lists in 137 countries. <i>Bulletin of the World Health Organization</i> , 2019, 97, 394-404C.	1.5	67
69	Marketing medicines: charting the rise of modern therapeutics through a systematic review of adverts in UK medical journals (1950-1980). <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1668-1685.	1.1	7
70	Variation in diagnostic test requests and outcomes: a preliminary metric for OpenPathology.net. <i>Scientific Reports</i> , 2018, 8, 4752.	1.6	12
71	Overtesting and undertesting in primary care: a systematic review and meta-analysis. <i>BMJ Open</i> , 2018, 8, e018557.	0.8	80
72	Overdiagnosis: what it is and what it isn't. <i>BMJ Evidence-Based Medicine</i> , 2018, 23, 1-3.	1.7	191

#	ARTICLE	IF	CITATIONS
73	Benefits and Harms in Pivotal Trials of Oral Centrally Acting Antiobesity Medicines: A Systematic Review and Meta-Analysis. <i>Obesity</i> , 2018, 26, 513-521.	1.5	4
74	Catalogue of bias: attrition bias. <i>BMJ Evidence-Based Medicine</i> , 2018, 23, 21-22.	1.7	101
75	Methods for meta-analysis of pharmacodynamic dose-response data with application to multi-arm studies of alogliptin. <i>Statistical Methods in Medical Research</i> , 2018, 27, 564-578.	0.7	6
76	Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 63-72.	1.0	18
77	Practice variation in the use of tests in UK primary care: a retrospective analysis of 16 million tests performed over 3.3 million patient years in 2015/16. <i>BMC Medicine</i> , 2018, 16, 229.	2.3	21
78	Temporal trends in use of tests in UK primary care, 2000-15: retrospective analysis of 250 million tests. <i>BMJ: British Medical Journal</i> , 2018, 363, k4666.	2.4	91
79	Examining the "psychopharmacology revolution" (1950-1980) through the advertising of psychoactive drugs in the <i>British Medical Journal</i> . <i>Journal of Psychopharmacology</i> , 2018, 32, 1056-1066.	2.0	5
80	The use of mechanistic evidence in drug approval. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 1166-1176.	0.9	23
81	Reduced Salt Intake for Heart Failure. <i>JAMA Internal Medicine</i> , 2018, 178, 1693.	2.6	65
82	What is a "complex systematic review"? Criteria, definition, and examples. <i>BMJ Evidence-Based Medicine</i> , 2018, 23, 127-130.	1.7	10
83	Redefining rapid reviews: a flexible framework for restricted systematic reviews. <i>BMJ Evidence-Based Medicine</i> , 2018, 23, 201-203.	1.7	90
84	A word about evidence: "rapid reviews" or "restricted reviews"? <i>BMJ Evidence-Based Medicine</i> , 2018, 23, 204-205.	1.7	15
85	Prescribing biosimilars. <i>BMJ: British Medical Journal</i> , 2018, 362, k3141.	2.4	10
86	Diagnostic test guidelines based on high-quality evidence had greater rates of adherence: a meta-epidemiological study. <i>Journal of Clinical Epidemiology</i> , 2018, 103, 40-50.	2.4	14
87	A brief history of clinical evidence updates and bibliographic databases. <i>Journal of the Royal Society of Medicine</i> , 2018, 111, 292-301.	1.1	3
88	Oral hormone pregnancy tests and the risks of congenital malformations: a systematic review and meta-analysis. <i>F1000Research</i> , 2018, 7, 1725.	0.8	10
89	Defining "nutraceuticals": neither nutritious nor pharmaceutical. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 8-19.	1.1	158
90	Poor medication adherence in clinical trials: consequences and solutions. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 149-150.	21.5	58

#	ARTICLE	IF	CITATIONS
91	CARE guidelines for case reports: explanation and elaboration document. <i>Journal of Clinical Epidemiology</i> , 2017, 89, 218-235.	2.4	993
92	Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification. <i>Drug Safety</i> , 2017, 40, 431-441.	1.4	7
93	Biomarkersâ€”A General Review. <i>Current Protocols in Pharmacology</i> , 2017, 76, 9.23.1-9.23.17.	4.0	196
94	The STROCSS statement: Strengthening the Reporting of Cohort Studies in Surgery. <i>International Journal of Surgery</i> , 2017, 46, 198-202.	1.1	727
95	Drugs for rare disorders. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1607-1613.	1.1	21
96	Post-marketing drug withdrawals: Pharmacovigilance success, regulatory problems. <i>Therapie</i> , 2017, 72, 555-561.	0.6	20
97	Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1328-1337.	0.9	2
98	Unlicensed and offâ€”label uses of medicines: definitions and clarification of terminology. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2615-2625.	1.1	55
99	Trials of transvaginal mesh devices for pelvic organ prolapse: a systematic database review of the US FDA approval process. <i>BMJ Open</i> , 2017, 7, e017125.	0.8	64
100	Ten essential papers for the practice of evidence-based medicine. <i>BMJ Evidence-Based Medicine</i> , 2017, 22, 202-204.	1.7	8
101	What evidence affects clinical practice? An analysis of Evidence-Based Medicine commentaries. <i>Evidence-Based Medicine</i> , 2017, 22, 197-197.	0.6	1
102	Shortâ€”and mediumâ€”term effects of light to moderate alcohol intake on glycaemic control in diabetes mellitus: a systematic review and metaâ€”analysis of randomized trials. <i>Diabetic Medicine</i> , 2017, 34, 604-611.	1.2	18
103	â€œCollaborative careâ€”is preferable to â€œpatient centred careâ€”. <i>BMJ, The</i> , 2016, 353, i2926.	3.0	7
104	Adverse events in patients taking cephalosporins versus placebo for any indication. <i>The Cochrane Library</i> , 2016, , .	1.5	0
105	Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review. <i>BMC Medicine</i> , 2016, 14, 191.	2.3	113
106	How similar are biosimilars?. <i>BMJ, The</i> , 2016, 353, i2721.	3.0	11
107	Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. <i>BMC Medicine</i> , 2016, 14, 10.	2.3	384
108	Evidence of Misclassification of Drugâ€”Event Associations Classified as Gold Standard â€”Negative Controlsâ€”™ by the Observational Medical Outcomes Partnership (OMOP). <i>Drug Safety</i> , 2016, 39, 421-432.	1.4	25

#	ARTICLE	IF	CITATIONS
109	The SCARE Statement: Consensus-based surgical case report guidelines. <i>International Journal of Surgery</i> , 2016, 34, 180-186.	1.1	1,585
110	The law of mass action and the pharmacological concentrationâ€“effect curve: resolving the paradox of apparently nonâ€“doseâ€“related adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 56-61.	1.1	19
111	Cato Guldberg and Peter Waage, the history of the Law of Mass Action, and its relevance to clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 52-55.	1.1	21
112	Preferred reporting of case series in surgery; the PROCESS guidelines. <i>International Journal of Surgery</i> , 2016, 36, 319-323.	1.1	351
113	Inhibiting the proton pump: mechanisms, benefits, harms, and questions. <i>BMC Medicine</i> , 2016, 14, 172.	2.3	14
114	Nominal ISOMERs (Incorrect Spellings Of Medicines Eluding Researchers)â€“variants in the spellings of drug names in PubMed: a database review. <i>BMJ, The</i> , 2016, 355, i4854.	3.0	6
115	Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2016, 30, 495-553.	2.0	755
116	Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis. <i>Critical Reviews in Toxicology</i> , 2016, 46, 477-489.	1.9	86
117	How a VOICE for clinical pharmacology turns into a RECIPE for its development. <i>Translational and Clinical Pharmacology</i> , 2016, 24, 1.	0.3	1
118	Photosensitivity reactions and skin tumours associated with voriconazole. <i>Adverse Drug Reaction Bulletin</i> , 2015, 290, 1119-1122.	0.6	0
119	Toward standardized reporting of drug interactions: the READI checklist for anecdotal reports. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 399-409.	1.3	3
120	A licence to cure. <i>BMJ, The</i> , 2015, 350, h1723-h1723.	3.0	1
121	Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis. <i>BMC Medicine</i> , 2015, 13, 26.	2.3	48
122	Quantifying the effects of diuretics and Î²â€“adrenoceptor blockers on glycaemic control in diabetes mellitus â€“ a systematic review and metaâ€“analysis. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 733-743.	1.1	46
123	Medication errors detected in non-traditional databases: types of errors in methotrexate dosing as listed in four different Danish registers. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1375-1379.	0.8	14
124	Pycnodysostosis and the making of an artist. <i>Gene</i> , 2015, 555, 59-62.	1.0	12
125	Patient Safety in Medication Nomenclature: Orthographic and Semantic Properties of International Nonproprietary Names. <i>PLoS ONE</i> , 2015, 10, e0145431.	1.1	15
126	The Need for Randomization in Animal Trials: An Overview of Systematic Reviews. <i>PLoS ONE</i> , 2014, 9, e98856.	1.1	199



#	ARTICLE	IF	CITATIONS
127	Medical eponyms: taxonomies, natural history, and the evidence. <i>BMJ</i> , The, 2014, 349, g7586-g7586.	3.0	14
128	Management of pain during injection of propofol. <i>Adverse Drug Reaction Bulletin</i> , 2014, 287, 1107-1110.	0.6	1
129	The adverse effects of nitrous oxide. <i>Adverse Drug Reaction Bulletin</i> , 2014, 285, 1099-1102.	0.6	2
130	Checklist for standardized reporting of drug-drug interaction management guidelines. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 313-318.	0.8	18
131	Towards a single VOICE for European clinical pharmacology: proposals for future developments. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1981-1984.	0.8	3
132	Distinguishing Hazards and Harms, Adverse Drug Effects and Adverse Drug Reactions. <i>Drug Safety</i> , 2013, 36, 147-153.	1.4	31
133	All-Cause and Cardiovascular Mortality in Middle-Aged People With Type 2 Diabetes Compared With People Without Diabetes in a Large U.K. Primary Care Database. <i>Diabetes Care</i> , 2013, 36, 2366-2371.	4.3	121
134	When I use a word ... Innovations--'The Births of Time'. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 1037-1039.	0.2	0
135	Evaluation of pharmacological evidence for forensic purposes. <i>International Journal of Risk and Safety in Medicine</i> , 2012, 24, 3-12.	0.3	1
136	Balanced prescribing - principles and challenges. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 566-572.	1.1	29
137	Selected National Pharmacovigilance Websites. <i>Drug Safety</i> , 2012, 35, 141-148.	1.4	2
138	Defining "Surveillance" in Drug Safety. <i>Drug Safety</i> , 2012, 35, 347-357.	1.4	26
139	Paradoxical and Bidirectional Drug Effects. <i>Drug Safety</i> , 2012, 35, 1.	1.4	49
140	Defining rewardable innovation in drug therapy. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 253-254.	21.5	47
141	What do clinical pharmacologists do? A questionnaire survey of senior UK clinical pharmacologists. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 161-169.	1.1	17
142	David Grahame Grahame-Smith. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 830-832.	1.1	0
143	A new taxonomy for describing and defining adherence to medications. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 691-705.	1.1	1,308
144	Finding a VOICE for UK clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 843-845.	1.1	4

#	ARTICLE	IF	CITATIONS
145	An agenda for UK clinical pharmacology: Research priorities in biomarkers and surrogate endpoints. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 900-907.	1.1	27
146	An agenda for UK clinical pharmacology: Monitoring drug therapy. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 917-923.	1.1	27
147	An agenda for UK clinical pharmacology: From basic to clinical neuropharmacology: targetophilia or pharmacodynamics?. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 959-967.	1.1	6
148	Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy. <i>PLoS ONE</i> , 2011, 6, e18578.	1.1	16
149	Integrating pharmacology and clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 787-790.	1.1	4
150	Low-Dose Adrenaline, Promethazine, and Hydrocortisone in the Prevention of Acute Adverse Reactions to Antivenom following Snakebite: A Randomised, Double-Blind, Placebo-Controlled Trial. <i>PLoS Medicine</i> , 2011, 8, e1000435.	3.9	154
151	A NEW TAXONOMY FOR DESCRIBING AND DEFINING ADHERENCE TO MEDICATIONS. <i>British Journal of Clinical Pharmacology</i> , 2011, 73, no-no.	1.1	63
152	Clinical pharmacology and therapeutics in the UK – a great instauration. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 111-117.	1.1	16
153	A manifesto for clinical pharmacology from principles to practice. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 3-13.	1.1	41
154	Evidence-based mechanistic reasoning. <i>Journal of the Royal Society of Medicine</i> , 2010, 103, 433-441.	1.1	81
155	A Systematic Review and Empirical Analysis of the Relation Between Dose and Duration of Drug Action. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 17-26.	1.0	6
156	Preventability of Drug-Related Harms – Part I. <i>Drug Safety</i> , 2010, 33, 985-994.	1.4	61
157	Preventability of Drug-Related Harms – Part II. <i>Drug Safety</i> , 2010, 33, 995-1002.	1.4	34
158	Reducing prescription errors. <i>Lancet, The</i> , 2010, 375, 461-462.	6.3	4
159	EIDOS. <i>Drug Safety</i> , 2010, 33, 15-23.	1.4	35
160	NICE and new: appraising innovation. <i>BMJ: British Medical Journal</i> , 2010, 340, b5493-b5493.	2.4	41
161	Medication errors: what they are, how they happen, and how to avoid them. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2009, 102, 513-521.	0.2	188
162	From prescription-only to over-the-counter medicines ('PoM to P'): time for an intermediate category. <i>British Medical Bulletin</i> , 2009, 90, 63-69.	2.7	19

#	ARTICLE	IF	CITATIONS
163	Medication errors: problems and recommendations from a consensus meeting. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 592-598.	1.1	47
164	Medication errors: definitions and classification. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 599-604.	1.1	272
165	Medication errors: EMERGING solutions. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 589-591.	1.1	17
166	A Strategy for Regulatory Action When New Adverse Effects of a Licensed Product Emerge. <i>Drug Safety</i> , 2009, 32, 91-98.	1.4	17
167	Defining "Signal" and its Subtypes in Pharmacovigilance Based on a Systematic Review of Previous Definitions. <i>Drug Safety</i> , 2009, 32, 99-110.	1.4	119
168	The UK's NHS and pharma: need for more clinical pharmacologists. <i>Lancet, The</i> , 2009, 373, 1251-1252.	6.3	6
169	Evaluation and stages of surgical innovations. <i>Lancet, The</i> , 2009, 374, 1089-1096.	6.3	492
170	Patent medicines and secret remedies. <i>BMJ: British Medical Journal</i> , 2009, 339, b5415-b5415.	2.4	12
171	Clinical pharmacology "providing tools and expertise for translational medicine. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 154-157.	1.1	24
172	Publishing Histories of Adverse Reactions to Medicaments Anecdotally. <i>Drug Safety</i> , 2008, 31, 355-356.	1.4	5
173	Changing beta-blockers in heart failure: when is a class not a class?. <i>British Journal of General Practice</i> , 2008, 58, 387-389.	0.7	14
174	Something New Every Day. <i>Journal of Ambulatory Care Management</i> , 2008, 31, 65-68.	0.5	19
175	The diagnosis of art: Caravaggio's jaundiced Bacchus. <i>Journal of the Royal Society of Medicine</i> , 2007, 100, 429-430.	1.1	6
176	Give a drug a good name. <i>Lancet, The</i> , 2007, 369, 1326-1328.	6.3	4
177	Gold Standards in Pharmacovigilance. <i>Drug Safety</i> , 2007, 30, 645-655.	1.4	77
178	The diagnosis of art: Valentin le Rossignol and Ehlers-Danlos syndrome. <i>Journal of the Royal Society of Medicine</i> , 2007, 100, 193-194.	1.1	2
179	Adverse drug reactions ? no farewell to harms. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 131-135.	1.1	19
180	Editors' review of 2006 and the BJCP prize. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 1-4.	1.1	1

#	ARTICLE	IF	CITATIONS
181	Concentration-effect and dose-response relations in clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 255-257.	1.1	21
182	Compliance, concordance, adherence. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 383-384.	1.1	192
183	Communicating information about drug interactions. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 637-639.	1.1	22
184	Time to abandon the term "patient concordance". <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 711-713.	1.1	10
185	An agenda for research on adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 119-121.	1.1	2
186	Editors' Report for 2006. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 253-254.	1.1	0
187	Plagiarism "please don't copy". <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 403-405.	1.1	16
188	Old drugs "new uses". <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 563-565.	1.1	85
189	Clarification of Terminology in Medication Errors. <i>Drug Safety</i> , 2006, 29, 1011-1022.	1.4	207
190	The Diagnosis of Art: Melancholy and the Portrait of Dr Gachet. <i>Journal of the Royal Society of Medicine</i> , 2006, 99, 373-374.	1.1	3
191	The Diagnosis of Art: Exophthalmos "Gustave Doré's Ogre". <i>Journal of the Royal Society of Medicine</i> , 2006, 99, 421-421.	1.1	1
192	The Diagnosis of Art: Diastrophic Dysplasia and Hephaistos. <i>Journal of the Royal Society of Medicine</i> , 2006, 99, 584-585.	1.1	1
193	The Diagnosis of Art: Arthrogyposis and Ribera's The Clubfoot. <i>Journal of the Royal Society of Medicine</i> , 2006, 99, 321-322.	1.1	6
194	The Diagnosis of Art: Rachmaninov's Hand Span. <i>Journal of the Royal Society of Medicine</i> , 2006, 99, 529-530.	1.1	1
195	The diagnosis of art: melancholy and the Portrait of Dr Gachet. <i>Journal of the Royal Society of Medicine</i> , 2006, 99, 373-374.	1.1	3
196	The Diagnosis of Art: exophthalmos--Gustave Dore's ogre. <i>Journal of the Royal Society of Medicine</i> , 2006, 99, 421-421.	1.1	4
197	The Doctor in Literature: Satisfaction or Resentment?. <i>Health Expectations</i> , 2006, 9, 196-197.	1.1	0
198	Today's science, tomorrow's medicines. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 1-4.	1.1	2

#	ARTICLE	IF	CITATIONS
199	Medicines and the media. British Journal of Clinical Pharmacology, 2006, 61, 121-122.	1.1	1
200	Rare diseases and orphan drugs. British Journal of Clinical Pharmacology, 2006, 61, 243-245.	1.1	95
201	Monitoring for harms of therapy. British Journal of Clinical Pharmacology, 2006, 61, 365-366.	1.1	1
202	Editors' Report 2005. British Journal of Clinical Pharmacology, 2006, 61, 492-493.	1.1	0
203	Clinical Pharmacology: Past, Present, and Future. British Journal of Clinical Pharmacology, 2006, 61, 647-649.	1.1	14
204	Risk perception in drug therapy. British Journal of Clinical Pharmacology, 2006, 62, 135-137.	1.1	27
205	The NSAID roller coaster: more about rofecoxib. British Journal of Clinical Pharmacology, 2006, 62, 257-259.	1.1	11
206	Balanced prescribing. British Journal of Clinical Pharmacology, 2006, 62, 629-632.	1.1	39
207	Case reports of suspected adverse drug reactions—systematic literature survey of follow-up. BMJ: British Medical Journal, 2006, 332, 335-339.	2.4	84
208	Anecdotes that provide definitive evidence. BMJ: British Medical Journal, 2006, 333, 1267-1269.	2.4	162
209	Polypharmacy, appropriate and inappropriate. British Journal of General Practice, 2006, 56, 484-5.	0.7	25
210	Adjusting therapeutic dosage regimens to optimise the balance of benefit to harm. Clinical Medicine, 2005, 5, 16-19.	0.8	4
211	Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions. Journal of Evaluation in Clinical Practice, 2005, 11, 195-208.	0.9	30
212	National differences in publishing papers on adverse drug reactions. British Journal of Clinical Pharmacology, 2005, 59, 108-111.	1.1	16
213	Internationality. British Journal of Clinical Pharmacology, 2005, 59, 1-4.	1.1	1
214	Write on. British Journal of Clinical Pharmacology, 2005, 59, 141-142.	1.1	0
215	Moving about. British Journal of Clinical Pharmacology, 2005, 59, 263-264.	1.1	2
216	Biomarkers and surrogate endpoints. British Journal of Clinical Pharmacology, 2005, 59, 491-494.	1.1	225

#	ARTICLE	IF	CITATIONS
217	Editors' Report 2004. British Journal of Clinical Pharmacology, 2005, 60, 5-6.	1.1	0
218	Metameta-analysis. British Journal of Clinical Pharmacology, 2005, 60, 117-119.	1.1	4
219	Monitoring therapy. British Journal of Clinical Pharmacology, 2005, 60, 229-230.	1.1	4
220	One hundred years of atrial fibrillation. British Journal of Clinical Pharmacology, 2005, 60, 345-346.	1.1	5
221	Prescribing statins. British Journal of Clinical Pharmacology, 2005, 60, 457-458.	1.1	8
222	Structural features of phenol derivatives determining potency for activation of chloride currents via $\alpha 1$ homomeric and $\alpha 1 \beta 2$ heteromeric glycine receptors. British Journal of Pharmacology, 2005, 145, 916-925.	2.7	15
223	Drug development: more science, more education. British Journal of Clinical Pharmacology, 2005, 59, 377-378.	1.1	8
224	Commentary: Open access publishing: too much oxygen?. BMJ: British Medical Journal, 2005, 330, 759.1.	2.4	11
225	Clarification of Terminology in Drug Safety. Drug Safety, 2005, 28, 851-870.	1.4	221
226	The British Journal of Clinical Pharmacology Editors' Report for 2003. British Journal of Clinical Pharmacology, 2004, 57, 538-539.	1.1	0
227	On Being 30. British Journal of Clinical Pharmacology, 2004, 57, 1-5.	1.1	8
228	In defence of polypharmacy. British Journal of Clinical Pharmacology, 2004, 57, 119-120.	1.1	83
229	Rational prescribing, appropriate prescribing. British Journal of Clinical Pharmacology, 2004, 57, 229-230.	1.1	42
230	Drug interactions-information, education, and the British National Formulary. British Journal of Clinical Pharmacology, 2004, 57, 371-372.	1.1	13
231	On the waterfront - the breadth and depth of clinical pharmacology. British Journal of Clinical Pharmacology, 2004, 57, 693-694.	1.1	10
232	What is a clinical trial?. British Journal of Clinical Pharmacology, 2004, 58, 1-3.	1.1	65
233	Littluns and biguns. British Journal of Clinical Pharmacology, 2004, 58, 117-118.	1.1	4
234	Classifying drug interactions. British Journal of Clinical Pharmacology, 2004, 58, 343-344.	1.1	38

#	ARTICLE	IF	CITATIONS
235	Citation classics in the British Journal of Clinical Pharmacology, 1974-2003. British Journal of Clinical Pharmacology, 2004, 58, S699-S702.	1.1	3
236	Medicines regulation and clinical pharmacology. British Journal of Clinical Pharmacology, 2004, 58, 569-570.	1.1	5
237	A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. British Journal of Clinical Pharmacology, 2004, 57, 616-621.	1.1	54
238	Over-the-counter medicines. British Journal of Clinical Pharmacology, 2004, 58, 231-234.	1.1	16
239	An improved model for the binding of lidocaine and structurally related local anaesthetics to fast-inactivated voltage-operated sodium channels, showing evidence of cooperativity. British Journal of Pharmacology, 2004, 141, 47-54.	2.7	27
240	Medication errors resulting from the confusion of drug names. Expert Opinion on Drug Safety, 2004, 3, 167-172.	1.0	45
241	Live long and prosper: a mass strategy for treating the factors associated with ischaemic heart disease and stroke. Journal of Medical Screening, 2004, 11, 1-2.	1.1	5
242	Medication errors resulting from the confusion of drug names. Expert Opinion on Drug Safety, 2004, 3, 167-72.	1.0	25
243	Drugs and Renal Insufficiency. Surgery, 2003, 21, 104a-104e.	0.1	2
244	The British Journal of Clinical Pharmacology Editors' Report for 2002. British Journal of Clinical Pharmacology, 2003, 55, 329-330.	1.1	0
245	Features of this month's Journal. British Journal of Clinical Pharmacology, 2003, 56, 475-476.	1.1	0
246	Features of this month's Journal. British Journal of Clinical Pharmacology, 2003, 56, 347-348.	1.1	0
247	Features of this month's Journal. British Journal of Clinical Pharmacology, 2003, 56, 247-248.	1.1	0
248	Nurse prescribers & reporters. British Journal of Clinical Pharmacology, 2003, 56, 585-587.	1.1	4
249	Features of this month's Journal. British Journal of Clinical Pharmacology, 2003, 55, 223-224.	1.1	1
250	Features of this month's Journal. British Journal of Clinical Pharmacology, 2003, 55, 327-328.	1.1	0
251	Features of this month's Journal. British Journal of Clinical Pharmacology, 2003, 55, 493-494.	1.1	0
252	Features of this month's Journal. British Journal of Clinical Pharmacology, 2003, 56, 141-142.	1.1	1

#	ARTICLE	IF	CITATIONS
253	Features of this month's Journal. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 1-2.	1.1	2
254	Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2003, 361, 1935-1938.	6.3	125
255	Joining the DoTS: new approach to classifying adverse drug reactions. <i>BMJ: British Medical Journal</i> , 2003, 327, 1222-1225.	2.4	217
256	Anecdotes as evidence. <i>BMJ: British Medical Journal</i> , 2003, 326, 1346-1346.	2.4	89
257	Being wholistic. <i>Focus on Alternative and Complementary Therapies</i> , 2003, 8, 381-382.	0.1	1
258	Adverse drug reactions: keeping up to date. <i>Fundamental and Clinical Pharmacology</i> , 2002, 16, 49-56.	1.0	44
259	Disco dancing. <i>Cytopathology</i> , 2002, 13, 326-327.	0.4	0
260	Block of voltage-operated sodium channels by 2,6-dimethylphenol, a structural analogue of lidocaine's aromatic tail. <i>British Journal of Pharmacology</i> , 2002, 137, 285-293.	2.7	18
261	Francis Galton and the invention of terms for quantiles. <i>Journal of Clinical Epidemiology</i> , 2001, 54, 1191-1194.	2.4	3
262	Forbidden fruit. <i>Nature Medicine</i> , 2001, 7, 29-30.	15.2	16
263	Structural requirements for voltage-dependent block of muscle sodium channels by phenol derivatives. <i>British Journal of Pharmacology</i> , 2001, 132, 1916-1924.	2.7	34
264	Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. <i>BMC Medical Research Methodology</i> , 2001, 1, 7.	1.4	95
265	A tribute to Graham Dukes. <i>Side Effects of Drugs Annual</i> , 2000, 23, xxiii-xxvi.	0.6	0
266	"Where name and image meet"--the argument for "adrenaline". <i>BMJ: British Medical Journal</i> , 2000, 320, 506-509.	2.4	53
267	Autopathography: the patient's tale. <i>BMJ: British Medical Journal</i> , 2000, 321, 1599-1602.	2.4	54
268	Voltage-dependent blockade of normal and mutant muscle sodium channels by benzylalcohol. <i>British Journal of Pharmacology</i> , 2000, 130, 1321-1330.	2.7	10
269	Inhibition of Na <sup>+</sup> /K <sup>+</sup> -ATPase may be one mechanism contributing to potassium efflux and cell shrinkage in CD95-induced apoptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2000, 5, 153-163.	2.2	77
270	Adverse drug reactions: definitions, diagnosis, and management. <i>Lancet, The</i> , 2000, 356, 1255-1259.	6.3	2,294



#	ARTICLE	IF	CITATIONS
271	Medication errors, worse than a crime. <i>Lancet, The</i> , 2000, 355, 947-948.	6.3	67
272	A Dictionary of Pharmacology and Allied Topics (2nd edition). <i>Trends in Pharmacological Sciences</i> , 1999, 20, 125.	4.0	2
273	Abnormal function of potassium channels in platelets of patients with Alzheimer's disease. <i>Lancet, The</i> , 1998, 352, 1590-1593.	6.3	41
274	Iatrogenic chest pain: a case of 5-fluorouracil cardiotoxicity. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1996, 89, 953-956.	0.2	10
275	Effects of High External Concentrations of K <sup>+</sup> on 86Rb <sup>+</sup> Efflux in Human Platelets: Evidence for Na <sup>+</sup> /K <sup>+</sup> /2Cl <sup>-</sup> Co-Transport. <i>Clinical Science</i> , 1996, 91, 725-731.	1.8	3
276	Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. <i>British Journal of Clinical Pharmacology</i> , 1996, 42, 423-429.	1.1	106
277	Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. <i>British Journal of Clinical Pharmacology</i> , 1996, 42, 423-429.	1.1	82
278	Prolonged half-life of verapamil in a case of overdose: implications for therapy.. <i>British Journal of Clinical Pharmacology</i> , 1995, 39, 680-683.	1.1	35
279	Confusion Over Similar Drug Names Problems and Solutions. <i>Drug Safety</i> , 1995, 12, 155-160.	1.4	23
280	The upregulation of Na <sup>+</sup> ,K <sup>+</sup> -ATPase pump numbers in lymphocytes from the first-degree unaffected relatives of patients with manic depressive psychosis in response to in vitro lithium and sodium ethacrynate. <i>Journal of Affective Disorders</i> , 1995, 34, 33-39.	2.0	19
281	What's in a brand name?. <i>BMJ: British Medical Journal</i> , 1994, 308, 1140-1141.	2.4	9
282	Modelling circadian variation in the pharmacokinetics of non-steroidal anti-inflammatory drugs. <i>European Journal of Clinical Pharmacology</i> , 1993, 45, 357-61.	0.8	7
283	Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease.. <i>Gut</i> , 1992, 33, 1353-1357.	6.1	24
284	ABC of monitoring drug therapy. Cyclosporin.. <i>BMJ: British Medical Journal</i> , 1992, 305, 1491-1494.	2.4	14
285	ABC of monitoring drug therapy. Patient compliance.. <i>BMJ: British Medical Journal</i> , 1992, 305, 1009-1011.	2.4	35
286	Increase in Na <sup>+</sup> /K <sup>+</sup> pump numbers in vivo in healthy volunteers taking oral lithium carbonate and further upregulation in response to lithium in vitro.. <i>British Journal of Clinical Pharmacology</i> , 1992, 34, 535-540.	1.1	7
287	Reversal of the effects of a low extracellular potassium concentration on the number and activity of Na <sup>+</sup> /K <sup>+</sup> pumps in an epstein-barr virus-transformed human lymphocyte cell line. <i>Biochemical Pharmacology</i> , 1992, 43, 489-496.	2.0	3
288	Potassium channels in nervous tissue. <i>Biochemical Pharmacology</i> , 1992, 43, 11-14.	2.0	54

#	ARTICLE	IF	CITATIONS
289	Penicillin. <i>European Journal of Clinical Pharmacology</i> , 1992, 42, 1-9.	0.8	4
290	Altered in vitro adaptive responses of lymphocyte Na <sup>+</sup> ,K <sup>+</sup> -ATPase in patients with manic depressive psychosis. <i>Journal of Affective Disorders</i> , 1991, 21, 199-206.	2.0	44
291	The effect of nifedipine on the disposition of strontium gluconate used as a kinetic marker for calcium in healthy volunteers.. <i>British Journal of Clinical Pharmacology</i> , 1991, 32, 441-445.	1.1	2
292	Intravenous strontium gluconate as a kinetic marker for calcium in healthy volunteers.. <i>British Journal of Clinical Pharmacology</i> , 1991, 31, 423-427.	1.1	7
293	Antibiotics policies in the developing world. <i>European Journal of Clinical Pharmacology</i> , 1991, 41, 85-7.	0.8	10
294	The effect of oral salbutamol on cation transport measured in vivo in healthy volunteers.. <i>British Journal of Clinical Pharmacology</i> , 1990, 30, 383-390.	1.1	3
295	The Measurement of Transmembrane Cation Transport in vivo in Acute Manic Illness. <i>British Journal of Psychiatry</i> , 1989, 155, 501-504.	1.7	8
296	A study of the transport of lithium across the erythrocyte membrane in vivo and of the effects of the ion transport inhibitors digoxin and dipyridamole.. <i>British Journal of Clinical Pharmacology</i> , 1989, 27, 749-756.	1.1	6
297	The Effect of Lithium on Cation Transport Measured in vivo in Patients Suffering from Bipolar Affective Illness. <i>British Journal of Psychiatry</i> , 1989, 155, 504-510.	1.7	21
298	Standardization of symbols in clinical pharmacology. <i>European Journal of Clinical Pharmacology</i> , 1988, 35, 1-7.	0.8	62
299	In vivo cation transport during short-term and long-term digoxin therapy.. <i>British Journal of Clinical Pharmacology</i> , 1986, 22, 27-30.	1.1	2
300	The effects of serum, lithium, ethacrynic acid, and a low external concentration of potassium on specific [ <sup>3</sup> H]ouabain binding to human lymphocytes after incubation for 3 days.. <i>British Journal of Clinical Pharmacology</i> , 1986, 22, 275-279.	1.1	14
301	Glycosides of plants and men. <i>Medical Journal of Australia</i> , 1986, 144, 505-506.	0.8	6
302	Cation transport abnormalities in vivo in untreated essential hypertension. <i>Clinical Science</i> , 1986, 70, 611-616.	1.8	10
303	Transdermal hyoscine (scopolamine) and postoperative vomiting. <i>Anaesthesia</i> , 1986, 41, 1-3.	1.8	33
304	The pharmacokinetics of L-tryptophan following its intravenous and oral administration.. <i>British Journal of Clinical Pharmacology</i> , 1985, 20, 317-321.	1.1	10
305	A sensitive high-temperature electrothermal atomic absorption analysis for Rb <sup>+</sup> in erythrocytes and plasma of normal and hypertensive persons. <i>Clinical Chemistry</i> , 1985, 31, 274-6.	1.5	4
306	Measurement of specific [ <sup>3</sup> H]ouabain binding to different types of human leucocytes.. <i>British Journal of Clinical Pharmacology</i> , 1984, 18, 153-161.	1.1	24

#	ARTICLE	IF	CITATIONS
307	Cardiac glycosides and drugs used in dysrhythmias. Side Effects of Drugs Annual, 1984, 8, 174-181.	0.6	1
308	The role of the Na <sup>+</sup> ,K <sup>+</sup> -ATPase in the regulation of vascular smooth-muscle contractility, and its relationship to essential hypertension. Biochemical Society Transactions, 1984, 12, 943-945.	1.6	7
309	Clinical Pharmacokinetics of Cardiac Glycosides in Patients with Renal Dysfunction. Clinical Pharmacokinetics, 1983, 8, 155-178.	1.6	22
310	Indications for the Measurement of Plasma Digoxin Concentrations. Drugs, 1983, 26, 230-242.	4.9	40
311	Pharmacokinetic investigation of the interaction of azapropazone with phenytoin.. British Journal of Clinical Pharmacology, 1983, 15, 727-734.	1.1	25
312	Cardiac glycosides and drugs used in dysrhythmias. Side Effects of Drugs Annual, 1983, 7, 193-209.	0.6	1
313	Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.. Gut, 1982, 23, 1081-1087.	6.1	144
314	The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.. British Journal of Clinical Pharmacology, 1982, 13, 523-528.	1.1	116
315	Lack of effect of phenytoin on functions related to Na <sup>+</sup> ,K <sup>+</sup> -ATPase activity of the intact erythrocytes of epileptic patients.. British Journal of Clinical Pharmacology, 1981, 12, 79-81.	1.1	1
316	Techniques for studying the pharmacodynamic effects of cardiac glycosides on patients' own erythrocytes during glycoside therapy. Klinische Wochenschrift, 1981, 59, 1323-1332.	0.6	16
317	Metabolism of an oral tryptophan load. I: Effects of dose and pretreatment with tryptophan.. British Journal of Clinical Pharmacology, 1980, 10, 603-610.	1.1	49
318	Clinical Pharmacokinetics of Digoxin 1980. Clinical Pharmacokinetics, 1980, 5, 137-149.	1.6	98
319	The characteristics of the binding of [ <sup>3</sup> H]-digoxin to the membranes of intact human erythrocytes: relevance to digoxin therapy.. British Journal of Clinical Pharmacology, 1979, 8, 115-124.	1.1	31
320	Changes in cardiac glycoside receptor sites, rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation.. British Journal of Clinical Pharmacology, 1979, 8, 125-134.	1.1	35
321	The acute changes seen in cardiac glycoside receptor sites, rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: pharmacological and therapeutic implications for chronic digoxin therapy.. British Journal of Clinical Pharmacology, 1979, 8, 135-142.	1.1	61
322	Tranlycypromine (Parnate™) overdose: measurement of tranlycypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. Psychological Medicine, 1979, 9, 377-382.	2.7	60
323	Monitoring digoxin therapy: III. How useful are the nomograms?. British Journal of Clinical Pharmacology, 1978, 5, 55-64.	1.1	24
324	Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response.. British Journal of Clinical Pharmacology, 1977, 4, 213-221.	1.1	44

#	ARTICLE	IF	CITATIONS
325	Monitoring digoxin therapy: II. Determinants of the apparent volume of distribution.. British Journal of Clinical Pharmacology, 1977, 4, 223-227.	1.1	24
326	ALTERED DISTRIBUTION OF DIGOXIN IN RENAL FAILURE“ A CAUSE OF DIGOXIN TOXICITY?. British Journal of Clinical Pharmacology, 1976, 3, 1045-1051.	1.1	55
327	DIGOXIN THERAPY: TEXTBOOKS, THEORY AND PRACTICE. British Journal of Clinical Pharmacology, 1976, 3, 639-648.	1.1	17
328	Adverse events in patients taking macrolide antibiotics versus placebo for any indication. The Cochrane Library, 0, , .	1.5	15
329	Biomarkers and Surrogate Endpoints in Monitoring Therapeutic Interventions. , 0, , 48-62.		9
330	Good Practice in Delivering Laboratory Monitoring. , 0, , 166-178.		0
331	Monitoring Cholesterol-Modifying Interventions. , 0, , 245-253.		1
332	Monitoring Intraocular Pressure in Glaucoma. , 0, , 325-334.		0
333	Monitoring the Initial Response to Treatment. , 0, , 75-89.		0
334	When I use a word . . . . Medical counterfactuals. BMJ, The, 0, , o1267.	3.0	0
335	When I use a word . . . . Counterfactual medical history: the death of Charles II. BMJ, The, 0, , o1345.	3.0	1
336	When I use a word . . . . Medical words of 1952“ a jubilee celebration. BMJ, The, 0, , o1394.	3.0	0
337	When I use a word . . . . Counterfactual medical history: Milton“s blindness. BMJ, The, 0, , o1441.	3.0	2
338	When I use a word . . . . Counterfactual medical history: Milton“s treatment. BMJ, The, 0, , o1505.	3.0	1
339	When I use a word . . . . Counterfactual medical history: Milton“s poetry. BMJ, The, 0, , o1569.	3.0	0
340	When I use a word . . . . Values. BMJ, The, 0, , o1636.	3.0	0
341	When I use a word . . . . Unnecessary, hateful, sickening words. BMJ, The, 0, , o1693.	3.0	0
342	When I use a word . . . . Too much medicine. BMJ, The, 0, , o1775.	3.0	2